Engelmann, Cornelius
Adebayo, Danielle
Oria, Marc
De Chiara, Francesco
Novelli, Simone
Habtesion, Abeba
Davies, Nathan
Andreola, Fausto
Jalan, Rajiv
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (EN 1100/2-1)
The study was partially funded through an unfettered donation to UCLH Charities by Am Pharma
Article History
Received: 17 July 2019
Accepted: 9 November 2019
First Online: 15 January 2020
Competing interests
: Rajiv Jalan has research collaborations with Takeda, and Yaqrit, and consults for Yaqrit. Rajiv Jalan is the founder of Yaqrit Limited, which is developing UCL inventions for treatment of patients with cirrhosis. Rajiv Jalan is an inventor of ornithine phenylacetate, which was licensed by UCL to Mallinckrodt. He is also the inventor of Yaq-001, DIALIVE and Yaq-005, the patents for which have been licensed by his University into a UCL spinout company, Yaqrit Ltd. Cornelius Engelmann has on-going research collaboration with Merz Pharmaceutical and Novartis. He has received speaker fees from Novartis, Gilead and Merz Pharmaceuticals. No other authors declared conflicts of interest.